

Communication

Not peer-reviewed version

Evaluation of Neutralizing Antibodies on Respiratory Syncytial Virus in Japanese Mother-Infant Pairs after COVID-19 Pandemic

[Tomohiro Oishi](#)*, [Daisuke Yoshioka](#), Sachie Ono, Yuto Yasui, Atsushi Kato, Satoko Ogita, [Tomoaki Tokutomi](#), [Mazumi Miura](#), Takahiro Eitoku, Hideo Enoki, Koichiro Shimoya, Takashi Nakano

Posted Date: 2 July 2024

doi: 10.20944/preprints202407.0131.v1

Keywords: Neutralizing antibodies, respiratory syncytial virus, mother,



Preprints.org is a free multidiscipline platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Communication

Evaluation of Neutralizing Antibodies on Respiratory Syncytial Virus in Japanese Mother-Infant Pairs after COVID-19 Pandemic

Tomohiro Oishi *, Daisuke Yoshioka, Sachie Ono, Yuto Yasui, Atsushi Kato, Satoko Ogita, Tomoaki Tokutomi, Masumi Miura, Takahiro Eitoku, Hideo Enoki, Koichiro Shimoya and Takashi Nakano

Department of Clinical Infectious Diseases, Kawasaki Medical School, 577, Matsushima, Kurashiki 701-0192, Okayama, Japan; d-yoshi@med.kawasaki-m.ac.jp (D.Y.); sachie.ohno326@gmail.com (S.O.); yuto.ared.e31.h237.k5106@gmail.com (Y.Y.); katoatsu@med.kawasaki-m.ac.jp (A.K.); ogita@med.kawasaki-m.ac.jp (S.O.); tokutomi@med.kawasaki-m.ac.jp (T.T.); mmiura@med.kawasaki-m.ac.jp (M.M.); eitoku@med.kawasaki-m.ac.jp (T.E.); enokih.neuropediatr@med.kawasaki-m.ac.jp (H.E.); shimoya@med.kawasaki-m.ac.jp (K.S.); nakano@med.kawasaki-m.ac.jp (T.N.)

* Correspondence: oo0612@med.kawasaki-m.ac.jp

Abstract: Respiratory syncytial virus (RSV) is the most common cause of acute lower respiratory tract infection in young children globally. Following the COVID-19 pandemic, RSV infections have become more prevalent. Consequently, a new vaccine targeting RSV infections in pregnant women has been introduced worldwide. To estimate the effectiveness of this new vaccine for pregnant women, we investigated neutralizing antibodies against RSV in samples taken from 51 mothers and their babies. The prevalence rate of neonatal antibodies, defined as a titer of ≥ 16 , was 39.2%. We found no significant differences in neonatal neutralizing antibodies based on factors, such as sex, gestational age at birth, birth weight, presence of siblings, neonatal problem, and usage of palivizumab. Neonatal neutralizing antibodies were equal to or higher than those of their mother. A new RSV vaccine targeting all pregnant women is promising, as approximately 60% of neonates had low antibody titers against RSV. However, predicting low antibody titer against RSV remains challenging. Moreover, our findings indicate efficient transmission of RSV antibodies from babies to their mothers.

Keywords: neutralizing antibodies; respiratory syncytial virus; mother; neonate

1. Introduction

Respiratory syncytial virus (RSV) is the most common cause of acute lower respiratory infection in young children around the world. RSV infections, especially, cause severe respiratory diseases among children under 6 months old [1–3]. In Japan, around one-fourth of all patients with RSV <2 years were hospitalized, about 90 % of whom did not have an underlying risk factor. In 2017-2018, three to four out of every 100 Japanese children <6 months were hospitalized for RSV [4]. The prevalence of RSV decreased during the COVID-19 pandemic. However, RSV infections have been prevalent thereafter in Japan. Recently, a new vaccine for pregnant women has been introduced worldwide, including in Japan [5]. To assess the effectiveness of the RSV vaccine, we investigated the situation of antibody retention for RSV among pregnant women and transmissions from mothers to their babies.

2. Materials and Methods

2.1. Ethics Aspects

Informed consent was obtained from the children or their parents. The study protocol was approved by the Ethics Committee of Kawasaki Medical School, Kurashiki, Japan, on 1 August 2023 (no. 5370-04).

2.2. Participants

We enrolled pregnant women who were admitted for their pregnancies at Kawasaki Medical School Hospital from March 2023 to February 2024. We obtained their consent and collected blood samples from them and their cord blood at delivery. We also checked their gestation age at delivery and their ages. Furthermore, we investigated their babies’ sex, Apgar scores at 5 minutes, outcomes, and birth weights.

2.3. Measurement of Neutralizing Antibody on Respiratory Syncytial Virus (RSV)

We assayed serum neutralizing antibodies on RSV in a microtitration system using standard techniques previously reported [6]. The dilutions were started at 1:4 and up to 1:320, and we assessed more than 1:16 as enough antibody titer to protect against RSV infections based on a previous report [7].

2.4. Statistical Methods

GraphPad Prism 5 (GraphPad Software Inc., San Diego, CA, USA) was used for statistical analysis. Differences between the two groups were analyzed using chi-square test, Student’s t-test, Fisher’s exact test, or Mann–Whitney U test, and the 95% confidence interval was determined. P values of <0.05 were considered significant.

3. Results

3.1. Participants

From March 2023 to February 2024, a total of 51 children and their 51 mothers who were admitted to Kawasaki Medical School Hospital during the investigation period were enrolled.

3.2. Characteristics of the Maternal and Infant Participants

Table 1 shows the characteristics of the maternal and infant participants. Among the 51 maternal participants, the mean and median gestation at delivery were 37.5 and 38 weeks, respectively. The mean and median age of the mothers were 29.8 and 29 years old, respectively.

Among the 51 infants participants, 31 (60.8%) were male and 20 (39.2%) were female. Among them, 15 (29.4%) were born at <37 weeks, indicating preterm delivery. None had Apgar scores of less than seven points at 5 minutes. Regarding their outcomes, 38 (74.5%) were normal. However, nine (17.7%) had congenital malformations or anomalies, one (2.0%) had developmental delays, and three (5.9%) had other neonatal problems. Among the total babies, 15 (29.4%) had low birth weights, including one very low birth weight baby. Nine (17.7%) infants received palivizumab, and 16 (31.4%) had siblings.

Table 1. Characteristics of the maternal and infants participants.

Maternal participants	
Gestation at delivery – wk	
Mean	37.5±2.2
Median (range)	38(33–41)
Age	

Mean	29.8±5.3
Median (range)	29(20-39)
Infant participants	
Sex — no./total no. (%)	
Male	31/51 (60.8)
Female	20/51 (39.2)
Gestational age at birth — no./total no. (%)	
24 to <28 wk	0/51 (0.0)
28 to <34 wk	2/51 (3.9)
34 to <37 wk	13/51 (25.5)
37 to <42 wk	36/51 (70.6)
≥42 wk	0/51 (0.0)
Apgar score, 5 min	
<4 — no./total no. (%)	0/51 (0.0)
4 to <7 — no./total no. (%)	0/51 (0.0)
7 to 10 — no./total no. (%)	51/51 (60.8)
Median (range)	9 (9–9)
Outcome — no./total no. (%)	
Normal	38/51 (74.5)
Congenital malformation or anomaly	9/51 (17.7)
Developmental delay — no./total no. (%)‡	1/51 (2.0)
Other neonatal problems	3/51 (5.9)
Extremely low birth weight, ≤1000 g — no./total no. (%)	0/51 (0.0)
Very low birth weight, >1000 to 1500 g — no./total no. (%)	1/51 (2.0)
Low birth weight, >1500 to 2500 g — no./total no. (%)	15/51 (29.4)
Usage of palivizumab	9/51 (17.7)
Presence of siblings	16/51 (31.4)

3.3. Maternal Neutralizing Antibody on Respiratory Syncytial Virus (RSV)

Maternal neutralizing antibody titers against RSV are shown in Table 2. The geometric mean titer (GMT) was 7.9, and the antibody prevalence rate, defined as an antibody titer of ≥ 16, was 21.6%. Mothers aged ≥35 years had a GMT of 5.7 and an antibody prevalence rate of 16.7%, while mothers aged <35 years had a GMT of 8.5 and an antibody prevalence rate of 23.1%. Mothers who gave birth at < 37 weeks had a GMT of 6.4 and an antibody prevalence rate of 6.7%, while those who gave birth at ≥37 weeks had a GMT of 8.8 and an antibody prevalence rate of 27.8%. Mothers who delivered by cesarean section had a GMT of 7.7 and an antibody prevalence rate of 14.3%, while those who had other types of delivery had a GMT of 8.2 and an antibody prevalence rate of 27.8%. Mothers with a history of previous deliveries had a GMT of 8.4 and an antibody prevalence rate of 17.7%, while those without a history of previous deliveries had a GMT of 7.6 and an antibody prevalence rate of 23.5%. No significant differences in GMT and antibody prevalence among these categories were observed.

Table 2. Maternal neutralizing antibody on respiratory syncytial virus (RSV).

Neutralizing antibody on RSV		Total (N=51)	
Geometric mean titer		7.9	
Antibody prevalence rate*		21.6% (11/51)	
Mother of 35-year-old and above	Yes	No	P-value
Geometric mean titer	5.7 (n=12)	8.5 (n=39)	P=0.30
Antibody prevalence rate*	16.7% (2/12)	23.1% (9/39)	P=1.0
Gestational age at birth	<37 wk	≥37 wk	
Geometric mean titer	6.4 (n=15)	8.8 (n=36)	P=0.10
Antibody prevalence rate*	6.7% (1/15)	27.8% (10/36)	P=0.14

Type of delivery	Cesarean section	Normal or vacuum	
Geometric mean titer	7.4 (n=21)	8.2 (n=30)	P=0.94
Antibody prevalence rate*	14.3% (3/21)	27.8% (8/30)	P=0.50
Past history of delivery	Yes	No	
Geometric mean titer	8.4 (n=17)	7.6 (n=34)	P=0.54
Antibody prevalence rate*	17.7% (3/17)	23.5% (8/34)	P=0.73

*≥ 16 of antibody titer.

3.4. Neonatal Neutralizing Antibody on Respiratory Syncytial Virus (RSV)

Table 3 shows neonatal neutralizing antibody titers against RSV. The GMT was 10.6, and the antibody prevalence rate, defined as an antibody titer of ≥16, was 39.2%. Neonates had a GMT of 9.9 and an antibody prevalence rate of 35.5%, while female neonates had a GMT of 11.7 and an antibody prevalence rate of 45.0%. Neonates born at less than 37 weeks had a GMT of 9.6 and an antibody prevalence rate of 40.0%, while those born at 37 weeks or more had a GMT of 11.1 and an antibody prevalence rate of 38.9%. Neonates with siblings had a GMT of 12.7 and an antibody prevalence rate of 41.2%, while those without siblings had a GMT of 9.8 and an antibody prevalence rate of 38.2%. Neonates with any problems, including congenital malformations or anomalies, developmental delays, and other neonatal problems, had a GMT of 13.5 and an antibody prevalence rate of 50.0%, while those without such problems had a GMT of 9.8 and an antibody prevalence rate of 35.9%. Neonates who received palivizumab had a GMT of 10.4 and an antibody prevalence rate of 37.5%, while those who did not receive palivizumab had a GMT of 10.7 and an antibody prevalence rate of 37.8%. No significant difference in GMT and antibody prevalence among these categories was observed.

Table 3. Neonatal neutralizing antibody on respiratory syncytial virus (RSV).

Neutralizing antibody on RSV		Total (N=51)	
Geometric mean titer		10.6	
Antibody prevalence rate*1		39.2% (20/51)	
Sex	Male	Female	P-value
Geometric mean titer	9.9(n=31)	11.7(n=20)	P=0.36
Antibody prevalence rate*1	35.5% (11/31)	45.0% (9/20)	P=0.50
Gestational age at birth	<37 wk	≥37 wk	
Geometric mean titer	9.6(n=15)	11.1(n=36)	P=0.26
Antibody prevalence rate*1	40.0% (6/15)	38.9% (14/36)	P=0.94
Low birth weight (2500 or <2500g)	Yes	No	
Geometric mean titer	14.6(n=16)	9.2(n=35)	P=0.07
Antibody prevalence rate*1	50.0% (8/16)	34.3% (12/35)	P=0.29
Siblings	Yes	No	
Geometric mean titer	12.7 (n=17)	9.8 (n=34)	P=0.58
Antibody prevalence rate*1	41.2% (7/17)	38.2% (13/34)	P=0.83
Neonatal problems*2	Yes	No	
Geometric mean titer	13.5(n=12)	9.8 (n=39)	P=0.35
Antibody prevalence rate*1	50.0% (6/12)	35.9% (14/39)	P=0.38
Usage of palivizumab	Yes	No	

Geometric mean titer	10.4(n=16)	10.7 (n=37)	P=0.92
Antibody prevalence rate*1	37.5% (6/16)	37.8% (14/37)	P=0.98

*1≥16 of antibody titer; *2 Congenital malformation or anomaly, developmental delay, or other neonatal problems.

3.5. Comparison between Maternal and Neonatal Neutralizing Antibodies against RSV

A comparison between maternal and neonatal neutralizing antibodies against RSV is shown in Table 4. The GMT and antibody prevalence rates among mothers and neonates were 7.9 and 10.6, and 21.6% and 39.2%, respectively. The differences in maternal log2 antibody titers against RSV compared to their babies' titers were as follows: 17.7% of mothers had a titer that was -2 log2 lower than their babies' titers, 37.3% of mothers had a titer that was -1 log2 lower than their babies' titers, 37.3% of mothers had a titer equal to their babies' titers, 5.9% of mothers had a titer that was +1 log2 higher than their babies' titers, none of the mothers had a titer that was +2 log2 higher than their babies' titers. Therefore, no significant difference in GMT and antibody prevalence between mothers and their babies was observed. Almost all maternal antibody titers were equal to or less than their babies' titers.

Table 4. Comparison between maternal and neonatal neutralizing antibody against respiratory syncytial virus (RSV).

Neutralizing antibody on RSV	Mothers (N=51)	Neonates (N=51)	P-value
Geometric mean titer	7.9	10.6	P=0.14
Antibody prevalence rate*1	21.6% (11/51)	39.2% (20/51)	P=0.05
Differences in maternal Log2 antibody titers*2 of RSV from their babies' titers*2			
Mean ±SD	-0.67±0.80		
-2	17.7% (8/51)		
-1	37.3% (19/51)		
0	39.2% (20/51)		
1	5.9% (3/51)		
2	0.0% (0/51)		

4. Discussion

In our study, we collected 51 samples for neutralizing antibodies against RSV from mothers and their babies.

Regarding maternal neutralizing antibodies, the antibody prevalence rate was 21.6%. No significant difference in the GMT and antibody prevalence rates among different maternal ages, gestational ages, or delivery types was observed. Yildiz M et al. reported that the positive rate of anti-RSV antibody levels of puerperants measured by ELISA kits was 46.5% among puerperants in Istanbul, Turkey, in 2016 [8]. This rate is higher than that in our study. However, because the methods of measurement for RSV antibodies and the region and time of the studies were different, a direct comparison between this report and ours is not straightforward. In fact, Suara et al. reported that RSV- neutralizing-antibody titers in sera of mothers and newborns were significantly different between those residing in the Gambia and Houston [9]. Therefore, it is important to conduct surveys and comparisons in various terms and places in the future.

We also investigated neonatal neutralizing antibodies against RSV, finding that their antibody prevalence rate was 39.2%. No significant difference was observed in the GMT and antibody prevalence rates among different sexes, gestational ages at birth, birth weights, presence of siblings,

neonatal problems, and usage of palivizumab. According to the previously mentioned study by Yildiz M et al., the positive rate of anti-RSV antibodies in infants at birth was 61.5%⁸⁾, which was higher than our data. They also reported no significant differences in the level of natal antibodies among gender, frequency of gravidity, delivery type, gestational week, and birth weight⁸⁾, similar to our study.

In comparison between maternal and neonatal neutralizing antibodies against RSV, no significant difference was observed in GMT and antibody prevalence rates. However, the mean difference in maternal log₂ antibody titer of RSV was less than zero, indicating that neonatal antibody titers were higher than maternal ones for each mother-neonate pair. Chu et al. and Langley et al. reported that the cord-to-maternal RSV antibody transfer ratio was 1.03 and 1.15, respectively, indicating a similar tendency in our results [10,11].

There are some limitations to our study. First, we exclusively utilized the neutralizing antibody method to evaluate immunity against RSV. Other studies have employed ELISA kits to measure IgG for RSV [8–11], which are recognized for their high sensitivity and specificity [12]. However, neutralizing antibodies play a crucial role in preventing infection by rendering the virus non-infectious or less pathogenic [13]. Therefore, the neutralizing antibodies may reflect the ability to prevent infections. However, it is necessary to compare the effectiveness of these two methods, neutralizing antibodies and ELISA, in preventing RSV infections. We considered a neutralizing antibody titer of ≥ 16 as positive, following past reports [7]. However, to better understand the relationship between neutralizing antibody levels and the severity of RSV infections, it would be valuable to collect samples from children with RSV infections and assess the effectiveness of different antibody levels in preventing severe RSV infections.

Second, our data was collected from a single medical center. Immunity to RSV infections can vary significantly among different regions and over time [9]. Despite the global impact of RSV infections [14], collaborative efforts with other regions using standardized methods would allow for meaningful comparisons in the future.

Third, our study only sampled infants at birth. Research by Yildiz et al. indicates that the levels of IgG in infants decrease by the 6th month compared to those at birth.

Given that infants under 6 months are at higher risk for severe RSV infections, future studies should consider monitoring antibody levels up to at least 6 months after birth to better understand protective immunity over time.

5. Conclusions

We investigated neutralizing antibodies against RSV in Japanese mother-infant pairs after the COVID-19 pandemic. The antibody prevalence rate among mothers was 21.6%, while among their babies it was 39.2%. Despite investigating various factors affecting neonates, we did not find a significant difference in neutralizing antibodies against RSV, making it challenging to predict low levels of these antibodies. Furthermore, nearly all babies had neutralizing antibody titers at birth that were equal to or higher than those of their mothers. This suggests that an RSV vaccine targeting all pregnant women could be effective in preventing severe RSV infections in early infants.

Author Contributions: Conceptualization, D.Y., S.O., Y.Y., A.K., S.O., T.T., M.M., T.E., and H.E.; formal analysis, T.O.; writing—review and editing, K.S., T.N.; Writing—original draft, T.O. All authors have read and agreed to the published version of the manuscript

Funding: This research received no external funding.

Data Availability Statement: The raw data supporting the conclusions of this article will be made available by the corresponding author, Tomohiro Oishi on request.

Acknowledgments: We thank Reiji Kimura and Moeka Fujii for their technical assistance.

Conflicts of Interest: The authors declare no conflicts of interest.

References

1. Li 1, Y.; Wang 2, X.; Blau 3, D.M.; Caballero 4, M.T.; Feikin 5, D.R.; Gill 6, C.J.; Madhi 7, S.A.; Omer 8, S.B.; Simões 9, E.A.F.; Campbell 10, H.; et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. *Lancet* 2022, 399, 2047-2064.
2. Matias 1, G.; Taylor 2, R.; Haguinet 3, F.; Schuck-Paim 4, C.; Lustig 5 R.; Shinde 6, V. Estimates of hospitalization attributable to influenza and RSV in the US during 1997–2009, by age and risk status. *BMC Public Health* 2017, 17, 271.
3. Hall 1, C.B.; Simoes 2, E.A.; Anderson 3, L.J. Clinical and epidemiologic features of respiratory syncytial virus. *Curr Top Microbiol Immunol* 2013, 372, 39-57.
4. Kobayashi 1, Y.; Togo 2, K.; Agosti 3, Y.; McLaughlin 4, J. Epidemiology of respiratory syncytial virus in Japan: a nationwide claims database analysis. *Pediatr Int* 2022, 64, e14957.
5. Kampmann 1, B.; Madhi 2, S.A.; Munjal 3, I.; Simões 4, E.A.F.; Pahud 5, B.A.; Llapur 6, C.; Baker 7, J.; Marc 8, G.P.; Radley 9, D.; Shittu 10, E.; et al. Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. *N Engl J Med* 2023, 388, 1451-1464.
6. Henderson 1, F.W.; Collier 2, A.M.; Clyde 3, W.A. Jr.; Denny 4, F.W. Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children. *N Engl J Med* 1979, 300, 530-534.
7. Fernald 1, G.W.; Almond 2, J.R.; Henderson 3, F.W. Cellular and humoral immunity in recurrent respiratory syncytial virus infections. *Pediatr Res* 1983, 17:753-758.
8. Yildiz 1, M.; Kara 2, M.; Sutcu 3, M.; Mese 4, S.; Demircili 5, M.E.; Sivriköz 6, T.S., et al. Evaluation of respiratory syncytial virus IgG antibody dynamics in mother-infant pairs cohort. *Eur J Clin Microbiol Infect Dis* 2020, 39, 1279-1286.
9. Suara 1, R.O.; Piedra 2, P.A.; Glezen 3, W.P.; Adegbola 4, R.A.; Weber 5, M.; Mulholland 6, E.K.; Greenwood 7, B.M.; Whittle 8, H. Prevalence of neutralizing antibody to respiratory syncytial virus in sera from mothers and newborns residing in the Gambia and in the United States. *Clin Diagn Lab Immunol* 1996, 3, 477–479.
10. Chu 1, H.Y.; Tielsch 2, J.; Katz 3, J.; Magaret 4, A.S.; Khatry 5, S.; LeClerq 5, S.C.; Shrestha 6, L.; Kuypers 7, J.; Steinhoff 8, M.C.; Englund 9, J.A. Transplacental transfer of maternal respiratory syncytial virus (RSV) antibody and protection against RSV disease in infants in rural Nepal. *J Clin Virol* 2017, 95, 90-95.
11. Langley 1, G.F.; Anderson 2, L.J. Epidemiology and prevention of respiratory syncytial virus infections among infants and young children. *Pediatr Infect Dis J* 2011, 30, 510–517.
12. Crowther 1, J.R. Chapter 2: Basic Principles of ELISA. In *ELISA: theory and practice. Methods in molecular biology*; Humana Press, 1995; Vol. 42, pp. 35–62.
13. Klasse 1, P.J. Neutralization of virus infectivity by antibodies: old problems in new perspectives. *Adv Biol* 2014, 2014, 157895.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.